BFC Planning’s Zevra Therapeutics ZVRA Stock Holding History
Bought
Maintained
Sold
Other funds holding ZVRA
BFC Planning's ZVRA Position: Q3 2026 in Review
BFC Planning increased its Zevra Therapeutics (ZVRA) stake by 0.67% in Q3 2026, buying an estimated $119 and bringing the position to 1,510 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2140.
BFC Planning first reported a position in ZVRA in Q3 2024 and has held it in 9 quarters since. The position peaked at $21.5K in Q2 2026. 131 funds tracked by Wall St. Rank hold ZVRA as of Q3 2026.
- BFC Planning held 1,510 shares of Zevra Therapeutics worth $16.6K as of Q3 2026.
- BFC Planning bought 10 Zevra Therapeutics shares in Q3 2026, an estimated $119.
- Zevra Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2140 holding.
- BFC Planning first reported a position in Zevra Therapeutics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Zevra Therapeutics position peaked at $21.5K in Q2 2026.
- 131 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.